1. Home
  2. PGEN vs CET Comparison

PGEN vs CET Comparison

Compare PGEN & CET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Precigen Inc.

PGEN

Precigen Inc.

HOLD

Current Price

$3.81

Market Cap

1.4B

Sector

Health Care

ML Signal

HOLD

CET

Central Securities Corporation

HOLD

Current Price

$52.70

Market Cap

1.6B

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
PGEN
CET
Founded
1998
1929
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Finance/Investors Services
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
1.4B
1.6B
IPO Year
2013
N/A

Fundamental Metrics

Financial Performance
Metric
PGEN
CET
Price
$3.81
$52.70
Analyst Decision
Buy
Analyst Count
5
0
Target Price
$8.33
N/A
AVG Volume (30 Days)
4.0M
30.7K
Earning Date
05-13-2026
01-01-0001
Dividend Yield
N/A
5.12%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$230,981,000.00
N/A
Revenue This Year
$1,115.92
N/A
Revenue Next Year
$81.04
N/A
P/E Ratio
N/A
$6.93
Revenue Growth
N/A
N/A
52 Week Low
$1.30
$46.47
52 Week High
$5.47
$54.28

Technical Indicators

Market Signals
Indicator
PGEN
CET
Relative Strength Index (RSI) 38.10 49.99
Support Level $3.49 $52.23
Resistance Level $4.40 $53.95
Average True Range (ATR) 0.29 0.69
MACD -0.07 -0.06
Stochastic Oscillator 2.97 28.99

Price Performance

Historical Comparison
PGEN
CET

About PGEN Precigen Inc.

Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.

About CET Central Securities Corporation

Central Securities Corp is a non-diversified closed-end management investment company. The company's investment objective is long-term growth of capital. It invests in common stocks, bonds, convertible bonds, preferred stocks, convertible preferred stocks, warrants, options real estate, or short-term obligations of governments, banks, and corporations.

Share on Social Networks: